Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acamprosate appears to decrease alcohol intake in weaned alcoholics.

J P Lhuintre1, N Moore, G Tran

  • 1Unité d'Alcoologie, CHRU de Rouen, Hôpital de Boisguillaume, Boisguillaume, France.

Alcohol and Alcoholism (Oxford, Oxfordshire)
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Breaking the cell wall for efficient DNA delivery to diatoms.

Nature communications·2026
Same author

Suitability of botanical extracts as components of complex mixtures used in herbal tea infusions-challenges and opportunities.

Frontiers in pharmacology·2022
Same author

[Bilateral subdural hematomas due to idiopathic cerebral spinal fluid leak treated by radiologically guided blood patch].

Revue medicale de Liege·2022
Same author

[Chronic headaches due to idiopathic cerebrospinal fluid hypotension treated with sphenopalatine ganglion block].

Revue medicale de Liege·2022
Same author

Self-rated health in individuals with and without disease is associated with multiple biomarkers representing multiple biological domains.

Scientific reports·2021
Same author

Inhibition of MALT1 Decreases Neuroinflammation and Pathogenicity of Virulent Rabies Virus in Mice.

Journal of virology·2018
Same journal

Reduced ethanol consumption by mice treated orally with arachidonic acid alone or in combination with the benign yeast Saccharomyces cerevisiae.

Alcohol and alcoholism (Oxford, Oxfordshire)·2026
Same journal

Evaluating acute and post-acute COVID-19 symptoms among patients with and without alcohol-related cirrhosis: implications for quality management.

Alcohol and alcoholism (Oxford, Oxfordshire)·2026
Same journal

Interpretable machine learning for rare events: an inverse probability weighted application to understanding glucagon-like peptide-1 receptor agonists use and incident alcohol-related disorder.

Alcohol and alcoholism (Oxford, Oxfordshire)·2026
Same journal

Song audio features are associated with the presence of alcohol references in popular music lyrics.

Alcohol and alcoholism (Oxford, Oxfordshire)·2026
Same journal

Functional magnetic response imaging predictors of alcohol use disorder treatment outcome: a systematic review.

Alcohol and alcoholism (Oxford, Oxfordshire)·2026
Same journal

Natural language processing of patient in-session speech to predict brief motivational interviewing alcohol intervention response: an exploratory study.

Alcohol and alcoholism (Oxford, Oxfordshire)·2026
See all related articles

Acamprosate (calcium acetylhomotaurinate) significantly reduced markers of alcohol intake in alcoholics compared to placebo. This study suggests Acamprosate may be a new drug therapy for alcoholism.

Area of Science:

  • Pharmacology
  • Addiction Medicine
  • Clinical Trials

Background:

  • Alcoholism relapse is a significant public health concern.
  • Effective pharmacological interventions for alcohol dependence are needed.
  • Acamprosate is a medication investigated for its potential to reduce alcohol craving and relapse.

Purpose of the Study:

  • To evaluate the efficacy of Acamprosate (calcium acetylhomotaurinate) in reducing indicators of alcoholic relapse.
  • To compare Acamprosate's effects against a placebo in a double-blind, randomized, multicenter trial.

Main Methods:

  • A double-blind, placebo-controlled, randomized multicenter study.
  • Inclusion of 569 alcohol-dependent patients.
  • Assessment of plasma gamma-glutamyl transpeptidase (GGT) as a primary efficacy criterion over three months.

Related Experiment Videos

  • Analysis of various indicators of alcohol intake.

    • Main Results:

    • Acamprosate group showed significantly lower GGT levels (1.4 vs. 2.0 times normal, P=0.016) after three months.
    • Trends favored Acamprosate over placebo for other indicators of alcohol intake (P<0.05 or 0.05
    • Diarrhea was the most common side effect, occurring in 13% of Acamprosate patients versus 7% of placebo patients (P=0.04).

    Conclusions:

    • Acamprosate demonstrated superiority over placebo in improving markers of alcohol ingestion at three months.
    • Acamprosate may represent a novel therapeutic option for alcoholism treatment.
    • Its mechanism of action does not appear to involve antabuse, antidepressant, or conditioning effects.